Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ultragenyx Pharmaceutical Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
RARE
Nasdaq
2834
https://www.ultragenyx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ultragenyx Pharmaceutical Inc
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
- May 7th, 2024 8:30 pm
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q1 2024 Earnings Call Transcript
- May 4th, 2024 2:24 pm
Here's What Analysts Are Forecasting For Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) After Its First-Quarter Results
- May 4th, 2024 2:05 pm
Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ...
- May 3rd, 2024 7:01 pm
Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y
- May 3rd, 2024 4:22 pm
Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ...
- May 2nd, 2024 9:49 pm
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
- May 2nd, 2024 8:00 pm
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
- Apr 30th, 2024 8:00 pm
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
- Apr 30th, 2024 12:00 pm
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
- Apr 25th, 2024 8:30 pm
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Apr 19th, 2024 8:30 pm
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
- Apr 16th, 2024 3:33 pm
Ultragenyx says Angelman therapy is working, but safety questions remain
- Apr 15th, 2024 11:30 am
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
- Apr 15th, 2024 11:00 am
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
- Apr 12th, 2024 8:22 pm
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
- Apr 12th, 2024 12:00 pm
10 NASDAQ Stocks with Biggest Upside
- Mar 20th, 2024 12:11 pm
Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...
- Mar 12th, 2024 9:00 pm
Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)
- Mar 11th, 2024 7:00 pm
10 Biotech Stocks with Huge Potential
- Mar 8th, 2024 2:38 pm
Scroll